The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 35, No. 12, pp. 1559-1561. DOI 10.1345/aph.10406
© 2001 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rettman, K.
Right arrow Articles by McClintock, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rettman, K.
Right arrow Articles by McClintock, C


Research Articles

Hepatotoxicity after short-term trazodone therapy

KS Rettman and C McClintock

OBJECTIVE: To report a case of severe hepatotoxicity from a four-day course of trazodone in a patient being treated according to protocol in a detoxification center. CASE SUMMARY: A 46-year-old HIV-positive man with a past medical history of intravenous drug abuse and hepatitis C, who was well controlled with HIV medications, was admitted for cocaine withdrawal. The patient was started on a standard protocol at the detoxification center with methadone 50 mg/d, clonidine 0.1 mg twice daily for four days, and trazodone 200 mg/d for four days. Laboratory results showed acute hepatitis and cholestasis five days following admission. Trazodone and clonidine were discontinued at that time. His methadone and HIV regimens remained unchanged. Liver function test results were greatly improved 10 days after trazodone and clonidine discontinuation. DISCUSSION: This is the first case report of trazodone-induced liver damage after only a few days of therapy. Previous reports describe hepatitis developing after weeks to months of trazodone therapy. All comorbidities thought to affect the described laboratory abnormalities were ruled out as a cause by a hepatologist. The observation of the sudden rise and fall of liver enzymes is characteristic of a drug reaction in the absence of trauma and severe shock. CONCLUSIONS: Due to the temporal relationship of the introduction and withdrawal of trazodone in the medication regimen and the elevations in liver enzymes, we conclude that this patient experienced acute hepatitis induced by trazodone 200 mg/d therapy for four days. The findings of this case warrant caution and closer monitoring in a patient with multiple risk factors for liver damage.


This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
B. Wen, L. Ma, A. D. Rodrigues, and M. Zhu
Detection of Novel Reactive Metabolites of Trazodone: Evidence for CYP2D6-Mediated Bioactivation of m-Chlorophenylpiperazine
Drug Metab. Dispos., May 1, 2008; 36(5): 841 - 850.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
K. P DeSanty and C. M Amabile
Antidepressant-Induced Liver Injury
Ann. Pharmacother., July 1, 2007; 41(7): 1201 - 1211.
[Abstract] [Full Text] [PDF]


Home page
FocusHome page
M. A. Rifai and D. L. Rosenstein
Hepatitis C and Psychiatry
Focus, April 1, 2005; 3(2): 194 - 202.
[Abstract] [Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 2001 by Harvey Whitney Books Company.